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Abstract The aim of the English NHS Diabetic Eye
Screening Programme is to reduce the risk of sight loss
amongst people with diabetes by the prompt identification
and effective treatment if necessary of sight-threatening
diabetic retinopathy, at the appropriate stage during the
disease process. In order to achieve the delivery of evi-
dence-based, population-based screening programmes, it
was recognised that certain key components were required.
It is necessary to identify the eligible population in order to
deliver the programme to the maximum number of people
with diabetes. The programme is delivered and supported
by suitably trained, competent, and qualified, clinical and
non-clinical staff who participate in recognised ongoing
Continuous Professional Development and Quality Assur-
ance schemes. There is an appropriate referral route for
those with screen-positive disease for ophthalmology
treatment and for assessment of the retinal status in those
with poor-quality images. Appropriate assessment of con-
trol of their diabetes is also important in those who are
screen positive. Audit and internal and external quality
assurance schemes are embedded in the service. In Eng-
land, two-field mydriatic digital photographic screening is
offered annually to all people with diabetes aged 12 years
and over. The programme commenced in 2003 and reached
population coverage across the whole of England by 2008.
Increasing uptake has been achieved and the current annual
uptake of the programme in 2015–16 is 82.8% when 2.59
million people with diabetes were offered screening and
2.14 million were screened. The benefit of the programme
is that, in England, diabetic retinopathy/maculopathy is no
longer the leading cause of certifiable blindness in the
working age group.
Keywords Screening  Diabetic retinopathy  Blindness
Background
A reduction in diabetes-related blindness by at least one-
third was declared a primary objective for Europe in 1989
in the St. Vincent Declaration [1]. Countrywide popula-
tion-based diabetic retinopathy screening programmes have
developed in Iceland (17,200 with diabetes [2] in 2015),
Scotland (271,300 people [3] with diabetes), Wales
(183,300 people [3] with diabetes), Northern Ireland
(84,800 [3] people with diabetes) and England (2.91 mil-
lion people [3] with diabetes). Regional and local screening
programmes have developed in other parts of Europe [4]
and around the world. The cost of the English Screening
Programme is believed to be approximately 85.6 million
US dollars or 40 US dollars per person screened.
The Wilson and Junger criteria for a screening pro-
gramme, which are the 1968 principles [5] applied by the
World Health Organisation, formed the basis of the UK
National Screening Committee criteria for appraising the
viability, effectiveness and appropriateness of a screening
programme when the English NHS Diabetic Eye Screening
Programme commenced in 2003. I previously described
how we applied these principles to sight-threatening
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diabetic retinopathy to provide an evidence base [6, 7] for
the development of the programme.
It is important to realise the following principles of
screening:
1. Screening is a public health programme, not a
diagnostic test.
2. Large numbers of apparently healthy individuals are
invited for screening, and, if their screening test is
positive, offer further diagnostic investigation.
3. Some people may be harmed by the process, or falsely
reassured.
4. There is an ethical and moral responsibility to ensure
that the programmes are of high quality.
5. Quality Assurance of Screening programmes is there-
fore essential to ensure that the programme achieves
the highest possible standards and minimises harm.
These principles are fundamentally different to most
branches of medicine where tests are considered to be
diagnostic although, even in the circumstances of diag-
nostic tests, there will be some false positives and some
false negatives.
The sensitivity of a screening test is the percentage of
the condition that is correctly detected. If a screening test
has a sensitivity of 90%, this means that 1 in 10 is missed.
The specificity of a screening test is the percentage of
people that one refers unnecessarily. If a screening test is
90% specific, this means 1 in 10 is referred unnecessarily.
In 1995, a consensus view was put forward by clinicians at
a meeting of the British Diabetic Association in Exeter that
a screening test for diabetic retinopathy should have a
minimum specificity of 80% and a specificity of 95%. Most
studies on screening tests for diabetic retinopathy have
achieved over 85% against a recognised reference standard
and the specificity target of 95% has been achieved if the
numbers with ungradable images are not calculated as test
positive [8] but has proved more challenging to achieve
when they have been calculated as test positive [9, 10].
It is important that any information that is sent to people
who are offered screening tests explains to them that it will
not detect all people with the disease and that a small
number of people will be referred unnecessarily. It is also
important to explain in the literature that a screening test
for sight-threatening diabetic retinopathy will not pick up
all other eye conditions.
Stages in the development of the English NHS
diabetic eye screening programme
When developing the NHS Diabetic Eye Screening Pro-
gramme in England, we needed to consider 11 different
stages that are listed in Table 1.
It was critical for diabetologists, ophthalmologists,
public health doctors and optometrists to speak with one
voice; otherwise, we would never have established the
programme. Assessment and treatment facilities are avail-
able in England as part of our National Health Service, but
this question becomes much more relevant in developing
countries where treatment facilities may not be so readily
available. There is no point in screening for sight-threat-
ening diabetic retinopathy if treatment facilities are either
not available or inadequate.
In England, everyone has a Primary Care Physician
(GP) and so we have to obtain details from Primary Care
on those diagnosed with diabetes and everyone has an
NHS identifier number. A letter is sent out to everyone
with diabetes aged 12 years and over to invite them for a
diabetic eye screening appointment once a year. National
leaflets have been produced to explain about diabetic
retinopathy and about the screening test and what happens
if screen-positive diabetic retinopathy is found. We have
included information in the leaflet that the screening is not
a diagnostic test and hence will only detect at best 90% of
sight-threatening diabetic retinopathy and not other eye
conditions. There has also been active engagement with
patient organisations. There are appropriate exclusion
criteria for those who do not need to be invited for
screening, e.g. those already under ophthalmology and
terminally ill.
Software has been developed to provide a single collated
list of people with diabetes and for call recall, screening,
grading and audit. In the database, the images are attached
to patient details and confidentiality of patient data is a
priority. The database is regularly backed up and an IT
infrastructure has been established for capture and trans-
mission of images to and from the cameras.
In England, we use non-mydriatic cameras and under-
take mydriatic photography on all people with diabetes
aged 12 years and older. The two 45 fields captured by the
English Screening Programme are shown in Fig. 1 together
with the one 45 field used by Scotland and the seven 30
stereo fields that are used as a reference standard against
which screening tests are judged. The English Screening
Programme sets a minimum camera specification and tests
all prospective cameras that meet this minimum specifi-
cation on patients who are known to have specific features
of diabetic retinopathy. The specification document is a
fairly lengthy document which includes the following
statements: The unit must be capable of providing a min-
imum field of view of 45 horizontally and 40 vertically at
the specified resolution (at least 30 pixels/degree). The unit
must be capable of accommodating refractive errors
of ±15 D as detailed in EN ISO 10940. The internal fix-
ation aid should be capable of positioning the eye to cap-
ture the fields of regard specified below. The ‘field of
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regard’ of the fundus camera must make it relatively
straightforward for an appropriately trained and competent
retinal screener to capture images centred on (1) the foveal
area and (2) the optic disc. In addition, the ‘field of regard’
of the fundus camera must be able to capture images as
defined by the area covered by fields 3–7 of the seven-field
protocol used in the Early Treatment Diabetic Retinopathy
Study [11]. The list of cameras that are currently approved
to be used in the English Screening Programme is pub-
lished by Public Health England on their webpage [12].
There has been a progressive increase in the size of
uncompressed images from the modern camera backs
which are now over 20 MB—the English NHS Diabetic
Eye Screening Programme recommends capture of images
that are compressed to a size of 1–2 MB. This level of
compression has not been shown to lose any clinically
significant information [13–15].
When considering whether to routinely dilate the pupil
of people with diabetes attending for screening the study
that was influential in the decision-making process was a
Table 1 Stages and
considerations required in the
development of the English
Screening Programme
Stages Considerations
1 Manoeuvring around the politics of funding
2 Are assessment and treatment facilities available?
3 Identify cohort for invitation and call—recall
4 How to invite them?
5 Informing the patients and maximising uptake
6 Establish an IT infrastructure
7 Choose a camera and decide on compression levels for photographs
8 The test
9 The grading referral criteria and viewing of the images
10 Employ and train a competent workforce
11 Introduce Quality Assurance
Fig. 1 Photographic fields
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population-based screening study [16] of 1549 people with
diabetes who had received non-mydriatic one-field digital
photography followed by mydriatic two-field digital pho-
tography and a reference standard examination by an
experienced ophthalmologist whose examination was tes-
ted separately against seven-field stereo-photography [17].
The sensitivity for one-field non-mydriatic photography
was 86.0% (95% CI, 80.9–91.1%), the specificity was
76.7% (95% CI, 74.5–78.9%) and the poor-quality image
rate was 19.7% (95% CI, 18.4–21.0%). The sensitivity for
two-field mydriatic photography was 87.8% (95% CI,
83.0–92.6%), the specificity was 86.1% (95% CI,
84.2–87.8%) and a poor-quality image rate was 3.7% (95%
CI, 3.1–4.3%). This study led to the approach used in
England of two-field mydriatic photography and the
approach in Scotland of staged mydriasis with one-field
non-mydriatic photography and with dilation only if poor-
quality images were obtained. The correlation [18] with
age led Northern Ireland to only routinely dilate those aged
50 years and over.
It has been demonstrated that there is a strong correla-
tion [18] between age and poor-quality image rates in
diabetic retinopathy screening, for both non-mydriatic and
mydriatic photography. Hence, publications [19–22] with
small numbers in a young age range are not relevant to
population-based screening programmes where many of
the individuals to be screened are over 60 years.
In any population-based screening programme, it is
necessary to balance acceptability to the individuals being
screened and cost-effectiveness of the screening method
with detection rates of sight-threatening diabetic retinopa-
thy. Population-based screening programmes that use non-
mydriatic photography like the Scottish Screening Pro-
gramme [23] usually capture one field centred on the fovea
and those that use mydriatic photography like the English
Screening Programme usually capture a second field that is
centred on the disc, which also give a second view of the
macular area. In 1989, Moss [11] demonstrated that for
eight retinopathy levels, the rate of agreement with seven
stereoscopic fields ranges from 80% for two 30 stereo
fields to 91% for four 30 stereo fields. In 2003, Scanlon
[17] reported that two-field mydriatic digital photography
gave a sensitivity of 80.2% (75.2–85.2) and specificity of
96.2% (93.2–99.2) in comparison with seven-field stereo-
photography. In the latter study, 15.3% of seven-field sets
were ungradable compared with 1.5% of the two-field
digital photographs.
Clear protocols need to be in place for management of
people with poor-quality images. In the English Screening
Programme, all people with poor-quality images are
referred for examination by slit lamp biomicroscopy.
The English NHS Diabetic Eye Screening Programme
routinely measures Visual Acuity at screening, but it is
recognised that it is not sufficiently sensitive on its own to
be a screening tool [24, 25]. Hence, it needs to be used in
conjunction with other features that are detected at grading.
The diabetic retinopathy grading classification that has
the best evidence base is the Early Treatment Diabetic
Retinopathy Study (ETDRS) final Retinopathy Severity
Scale [26] because it provided the first detailed classifica-
tion system for retinopathy severity based on a natural
history study of untreated eyes. However, this relies on
detailed grading of stereo-photographs of seven fields of
each eye. This scale did not grade lesions in the macular
area. The ETDRS study did define ‘clinically significant
macular oedema’ which was a level at which laser treatment
was advised, but this was based on stereo-photography and
the study did not recommend a referral level for closer
observation before laser treatment was recommended.
Table 2 shows the International Classification [27]
which was developed by the American Academy of Oph-
thalmology in 2002 and recommends that any level of
retinopathy more severe than mild retinopathy (defined as
the presence of microaneurysms only) warrants examina-
tion by an ophthalmologist. However, this is too early a
referral level for use in the English Screening Programme
and the referral level for the English Screening Programme
is also listed in Table 2.
Table 3 shows the risks of progression to proliferative
diabetic retinopathy as recorded in the Early Treatment
Diabetic Retinopathy Study [26]. Screening Programmes
need to accept a certain level of risk. In the English pro-
gramme, we needed to decide whether we were prepared to
accept a 6.2% risk or an 11.3% risk that a patient who has
been screened and given a 1-year appointment develops
proliferative DR before their next screen. We opted for the
11.3% risk which is the equivalent to moderate non-pro-
liferative diabetic retinopathy on the ETDRS final
Retinopathy Severity Scale [26]. We also had to develop a
definition for maculopathy referral based on two-dimen-
sional markers. The ETDRS study did not classify macu-
lopathy, but it did make recommendations on what
constituted clinically significant macular oedema requiring
laser treatment as shown in Table 4. We opted for three
referral criteria, based on two-dimensional photographic
markers and measurement of Visual Acuity:
1. Exudate within 1 disc diameter (DD) of the centre of
the fovea (Fig. 2).
2. Circinate or group of exudates within the macula
(Fig. 3).
3. Any microaneurysm or haemorrhage within 1DD of
the centre of the fovea only if associated with a best
VA of B 6/12 (if no stereo) (Fig. 4).
A minimum screen resolution is recommended [12]
when viewing the images for grading which has progressed
Acta Diabetol
123
as the technology of screens has advanced. The current
minimum acceptable standard for screen resolution is a
vertical resolution of 1080 (1920 9 1080) with an
achievable and recommended standard of a minimum of
1200 (1920 9 1200 or higher). It is recommended that a
minimum of 60% of the image should be viewable on the
grading screen to avoid too much scrolling to see the full
image.
To ensure that whole screening programme is provided
by a trained and competent workforce a minimum quali-
fication [28] is required for screeners and graders in the
English programme. Evidence of ongoing continuous
professional development and taking the monthly External
Quality Assurance Test sets [29, 30] is also required—all
1500 graders in the English Screening Programme are
required to take a monthly test set of 20 image sets and
their grading of these images is compared against a guide
grade. An International Version of the qualification [31]
and the monthly test and training set [32] for screeners
working outside the UK is available.
An important part of any screening programme is the
introduction of Quality Assurance. The purpose of intro-
ducing Quality Assurance is to reduce the probability of
error and risk, ensure that errors are dealt with competently
Table 2 International and English screening retinopathy classifications
‘International’ clinical classification [27] English Screening Programme [48]
Optimise medical therapy, screen at least annually R0
Currently screen
Annually
Ma’s only R1
Screen annually
Background
Microaneurysm(s) or HMa
Retinal haemorrhage(s)
Venous loop
Any exudate or cotton wool spots (CWS) in
the presence of other non-referable features
of DR
More than just micro
aneurysms but less severe
than severe NPDR
Refer to ophthalmologist
R2
Refer to ophthalmologist
Pre-proliferative
Venous beading
Venous reduplication
Intraretinal microvascular abnormality
(IRMA)
Multiple deep, round or blot haemorrhages
Severe NPDR
Any of the following:
(a) Extensive intraretinal
haem ([20) in 4 quadrants
(b) Definite venous beading in
2? quadrants
(c) Prominent IRMA in
1? quadrant
And no signs of PDR
Consider Scatter photocoagulation for type 2 diabetes
Neovascularisation
Vitreous/pre-retinal
haemorrhage
Scatter Photocoagulation without delay for patients with
vitreous haemorrhage or neovascularisation within 1 disc
diameter of the optic nerve head
R3A
Urgent referral to ophthalmologist
R3A. Proliferative
New vessels on disc (NVD)
New vessels elsewhere (NVE)
Pre-retinal or vitreous haemorrhage
Pre-retinal fibrosis ± tractional retinal
detachment
R3S
Follow-up annually within screening or at
appropriate interval in surveillance
R3S. Stable treated proliferative
Evidence of peripheral retinal laser treatment
AND
Stable retina from photograph taken at or
shortly after discharge from the hospital eye
service (HES)
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and sensitively, help professionals and organisations
improve year on year, and set and keep under review
national standards.
The NHS Diabetic Eye Screening Programme has
developed three Key Performance Indicators and nine other
Quality Standards [33]. These are given in Table 5 with the
three Key Performance Indicators being shown in the right-
hand column. A programme board which includes local
health service representatives and national Quality Assur-
ance team representatives oversees the results of a
programmes performance against the standards four times
a year, and if a programme is performing poorly, they are
expected to improve or the service may be recommissioned
to be provided by a different provider. Graders who per-
form poorly on test sets undergo extra training and have all
of their work second graded until their performance
improves.
In addition, an External Quality Assurance visit to all
regional programmes who undertake Diabetic Eye
Screening as part of the NHS Diabetic Eye Screening
Table 3 ETDRS Diabetic Retinopathy Classification of Progression to Proliferative DR
ETDRS final retinopathy severity
scale [26]
ETDRS
(final)
grade
Lesions Risk of progression to
PDR in 1 year
(ETDRS interim)
No apparent retinopathy 10
14, 15
DR absent
DR questionable
Mild non-proliferative diabetic
retinopathy (NPDR)
20 Micro aneurysms only
35
a
b
c
d
e
One or more of the following:
Venous loops[ definite in 1 field
SE, IRMA, or VB questionable
Retinal haemorrhages present
HE[ definite in 1 field
SE[ definite in 1 field
Level 30 = 6.2%
Moderate NPDR 43a
b
H/Ma moderate in 4–5 fields or severe in 1 field or
IRMA definite in 1–3 fields
Level 41 = 11.3%
Moderately severe NPDR 47
a
b
c
d
Both level 43 characteristics –
H/Ma moderate in 4–5 fields or severe in 1 field and IRMA
definite in 1–3 fields
or any one of the following:
IRMA in 4–5 fields
HMA severe in 2–3 fields
VB definite in 1 field
Level 45 = 20.7%
Severe NPDR 53
a
b
c
d
One or more of the following:
[ 2 of the 3 levels, 47 characteristics
H/Ma severe in 4–5 fields
IRMA[moderate in 1 field
VB[ definite in 2–3 fields
Level 51 = 44.2%
Level 55 = 54.8%
Mild PDR 61a
b
FPD or FPE present with NVD absent or
NVE = definite
Moderate PDR 65a
b
(1) NVE[moderate in 1 field or definite NVD with VH and PRH
absent or questionable or
(2) VH or PRH definite and NVE\moderate in 1 field and NVD
absent
High-risk PDR 71
a
b
c
d
Any of the following:
(1) VH or PRH[moderate in 1 field
(2) NVE[moderate in 1 field and VH or PRH definite in 1 field
(3) NVD = 2 and VH or PRH definite in 1 field
(4) NVD[moderate
High-risk PDR 75 NVD[moderate and definite VH or PRH
Advanced PDR 81 Retina obscured due to VH or PRH
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Programme is undertaken every 3 years. EQA visits are an
integral part of Diabetic Eye Screening Quality Assurance.
Formal EQA visits to a screening programme provide the
forum for a review of the whole multidisciplinary screen-
ing pathway and an assessment of the effectiveness of team
working within the screening centre and associated referral
sites.
Programme results
In the development of the programme, I calculated [7] that
the NHS Diabetic Eye Screening Programme had the
potential to reduce the prevalence of blindness in England
from 4200 people to under 1000 people based on UK
certification of blindness. If WHO definitions were used the
prevalence, incidence and potential reductions in blindness
are much greater. In 2014, Liew [34] reported on the causes
of blindness certifications in England and Wales in work-
ing age adults (16–64 years) in 2009–2010 and compared
these with figures from 1999 to 2000. For the first time in at
least five decades, diabetic retinopathy/maculopathy was
no longer the leading cause of certifiable blindness
amongst working age adults in England and Wales, having
been overtaken by inherited retinal disorders. This change
was considered to be due to the introduction of nationwide
diabetic retinopathy screening programmes in England and
Wales and improved glycaemic control. The era in which
this reduction in blindness occurred was during the period
when laser treatment was being used for maculopathy and
before the use of VEGF inhibitors for diabetic macular
oedema.
Table 4 ETDRS Maculopathy Classification
Early treatment diabetic retinopathy study Outcome
Clinically significant macular oedema [49] as defined by
A zone or zones of retinal thickening one disc area or larger, any part of which is within one disc diameter of the centre of the
macula
Consider
laser
Retinal thickening at or within 500 microns of the centre of the macula Consider
laser
Hard exudates at or within 500 microns of the centre of the macula, if associated with thickening of the adjacent retina (not
residual hard exudates remaining after disappearance of retinal thickening)
Consider
laser
Fig. 2 Exudate within 1 disc diameter (DD) of the centre of the fovea
Fig. 3 Circinate or group of exudates within the macula
Fig. 4 A microaneurysm within 1DD of the centre of the fovea
associated with a best VA of B 6/12
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In 2015–2016, the NHS Diabetic Eye Screening Pro-
gramme in England [35] offered screening to 2,590,082
with diabetes using two-field mydriatic digital photogra-
phy. There were 3,083,401 known people with diabetes in
England, but people who are under an ophthalmologist for
diabetic eye disease and certain other categories of people
(e.g. terminally ill) are not invited. A total of 2,144,007
with diabetes were screened (Uptake 82.8%). New regis-
trations to programmes in 2015–2016 were 326,587. There
were 7593 urgent referrals with proliferative retinopathy
and 52,597 referrals with screen-positive maculopathy or
pre-proliferative diabetic retinopathy. Rate of retinopathy
per 100,000 screened was 2807.
Future developments for the programme
Changes in technology have introduced three-dimensional
imaging in the form of Optical Coherence Tomography.
Table 5 Standards and key performance indicators in the English NHS Diabetic Eye Screening Programme
Standard Criteria Thresholds Key
performance
indicators
1 Proportion of the known eligible people with diabetes offered an appointment for
routine digital screening
Acceptable: C 95%
Achievable: C 98%
2 Proportion of people newly diagnosed with diabetes offered a first routine digital
screening appointment that is due to occur within 89 calendar days of the
programme being notified of their diagnosis
Acceptable: C 90%
Achievable: C 95%
3 Proportion of eligible people with diabetes offered an appointment for routine
digital screening occurring 6 weeks before or after their due date
Acceptable: C 95%
Achievable: C 98%
4 Proportion of people with diabetes offered an appointment for slit lamp
biomicroscopy 6 weeks before or after their due date
Thresholds, to be set
5 Proportion of people with diabetes on digital surveillance who have been offered
an appointment that occurs within a reasonable time of their follow-up period
Thresholds, to be set
6 Proportion of pregnant women with diabetes seen within 6 weeks of notification of
their pregnancy to the screening programme
Thresholds, to be set
7 The proportion of those offered routine digital screening who attend a digital
screening event where images are captured
Acceptable: C 75%
Achievable: C 85%
KPI 1
8 Proportion of eligible people with diabetes who have not attended for screening in
the previous 3 years
Thresholds, to be set
9 Proportion of eligible people with diabetes where a digital image has been obtained
but the final grading outcome is ungradable
Acceptable: 2–4%
10 Time between routine digital screening event or digital surveillance event or slit
lamp biomicroscopy event and printing of results letters to the person with
diabetes, GP and relevant health professionals
Acceptable: 85%\ 3 weeks
and 99%\ 6 weeks.
KPI 2
11 Time between routine digital screening event or digital surveillance event or slit
lamp biomicroscopy event and issuing the referral to the hospital eye service
1. Urgent
Acceptable: C 95% 2 weeks
Achievable: C 98% 2 weeks
2. Routine
Acceptable: C 90% 3 weeks
Achievable: C 95% 3 weeks
12 Time between screening event and first attended consultation at hospital eye
services or digital surveillance
1. Urgent
Acceptable: C 80% 6 weeks
Achievable: C 95% 6 weeks
2. Routine
Acceptable: C 70%
13 weeks
Achievable: C 95%
13 weeks
KPI 3
13 Time between digital screening event and first attended consultation in slit lamp
biomicroscopy surveillance
Acceptable: C 70% within
13 weeks
Achievable: C 95% within
13 weeks
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These machines are more costly than digital cameras and
are not felt to be cost-effective as a first-line screening tool
when 65% of the population of people with diabetes have
no retinopathy. However, there is a high possibility that
they will be introduced as a second-line screening tool for
screen-positive maculopathy using two-dimensional
markers. It is believed that, of the 52,597 referrals with
screen-positive maculopathy, only 20% actually require
treatment and a significant proportion of the remaining
80% could be followed up in a technician-led clinic [36]
that includes OCT images to exclude any significant dia-
betic macular oedema. Cost-effectiveness data are needed
before this can be introduced.
Extensive work has been done in the area [37–40] of
extended screening intervals for those at low risk. The UK
National Screening Committee agreed at their committee
on 19 November 2015 and published their recommendation
in January 2016 that:
(a) For people with diabetes at low risk of sight loss, the
interval between screening tests should change from
1 to 2 years.
(b) The current 1 -year interval should remain
unchanged for the remaining people at high risk of
sight loss.
The introduction of this extension of screening interval
for those with no retinopathy on two consecutive screens,
which is the current recommendation in England, is
dependent on software development for the programme.
The use of automated analysis is currently being eval-
uated for use in the English Screening Programme. A
recent HTA report [41] has been published on this topic.
There are different ways in which automated analysis could
be used:
(a) To classify images as no diabetic retinopathy or
diabetic retinopathy so that a human grader would
only need to look at those with diabetic retinopathy.
(b) To detect referral levels of retinopathy.
(c) To act as a quality assurance tool for retinopathy that
is missed.
(d) To determine which images are gradable and which
are ungradable.
Scanning laser ophthalmoscopes and wide-field imaging
have been widely studied [42–44], but this method has not
yet been shown to be cost-effective. The earlier devices
that provided wide-field imaging compromised [45] on the
detection of microaneurysms in the central field.
No hand-held device has ever been shown [46] to have
comparable sensitivities and specificities for the detection
of sight-threatening diabetic retinopathy to devices where
the camera is fixed and the patient’s head is placed on a
chin rest and forehead against a fixed band and cannot,
therefore, be recommended for population-based screening
at the present time.
OCT angiography is new technology [47] that is not
currently suitable for population-based screening.
Conclusions
Screening for sight-threatening diabetic retinopathy has
been shown to be very effective in England in reducing
blindness due to diabetic retinopathy and reducing the
number of vitrectomies being performed on advanced
disease.
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